Intervacc have now come to a phase where several challenges in clinical trials and manufacturing have been overcome. We see that our main product, Strangvac®, has satisfied expected results in efficacy studies and we have seen that manufacturing of components in the vaccine can be made with a cost effective process. In addition to the remaining steps to launch Strangvac®, we will strengthen the company´s business idea to become a leading company within animal health, which can provide the market with veterinary vaccines and pharmaceuticals.
This means that the company now takes a clear step towards becoming a company with several products rather than only one. We will thus spend further force on the development of a vaccine against a streptococcal infection in piglets. For our subsidiary Nordvacc it means that new distribution agreements recently have been signed and further discussions are presently going on.
External analyzes of the company are conducted by ABG Sundal Collier, among others, and these are presented at Introduce Equity Research.
Investor presentation August 27, 2018
CSO Jan-Ingmar Flock presents Intervacc and the development of a new generation of vaccines within animal health. Strangvac® – our vaccine against equine strangles is first and the development of two other vaccines INV274 and INV412 continues with new funding from Eurostars-2/Horizon 2020 and Vinnova.
Here you can see the recorded and transcribed presentation which is about 23 minutes including the following Q&A.